Effient News and Research

RSS

HCRI completes enrollment in dual antiplatelet therapy clinical trial

The Harvard Clinical Research Institute (HCRI) announced today that the enrollment phase of the DAPT Study has been successfully completed. The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

27 Sep 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta

The U.S. Food and drug Administration (FDA) has finally approved AstraZeneca's Brilinta blood thinner for patients with acute coronary syndrome - conditions, such as heart attack and angina.

20 Jul 2011

Accumetrics' VerifyNow P2Y12 Test receives CE mark approval for prognostic use

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy who are at greater risk for future cardiovascular events.

17 May 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Portola, Accumetrics sign agreement to develop and supply VerifyNow System

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an agreement with Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow System and VerifyNowTests for use in clinical trials.

3 Mar 2011

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

AstraZeneca’s new blood thinner that was pitched against Plavix, the world’s second-best selling drug failed to live up to expectations making stocks drop to a two year low, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.

20 Dec 2010

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Accumetrics, Inc., developer and marketer of the VerifyNow System, today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) Trial found that in patients with high residual platelet reactivity, doubling the maintenance dose of clopidogrel did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI).

19 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

Accumetrics secures $24 million in capital infusion

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009.

2 Sep 2010

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.

26 Aug 2010

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

New report compares efficacy of Plavix, Effient in treating patients with ACS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of acute coronary syndrome, 56 percent of surveyed interventional cardiologists who prescribe Bristol-Myers Squibb/Sanofi-Aventis' Plavix in high doses, consider it to be comparable in efficacy to Daiichi Sankyo/Eli Lilly's recently-launched Effient.

20 Jul 2010

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).

29 Jun 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Medico's Hirata to distribute Accumetrics' VerifyNow System in Japan

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed a new agreement with Medico's Hirata for distribution of its VerifyNow System in Japan.

18 May 2010

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

7 Apr 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010